Full Text View
Tabular View
No Study Results Posted
Related Studies
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission
This study is currently recruiting participants.
Verified April 2013 by Van Andel Research Institute
Study NCT01586260   Information provided by Van Andel Research Institute

First Received on April 24, 2012.   Last Updated on April 5, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neuroblastoma in Remission
Additional conditions recognized in this trial
Neuroblastoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Interventions listed in this trial
DFMO
Additional drug interventions recognized in this trial
Eflornithine
More general drug interventions related to this trial
Anti-Infective Agents
Antineoplastic Agents
Antiparasitic Agents
Antiprotozoal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Trypanocidal Agents
Sponsors listed in this trial
Giselle Sholler
Cancer Prevention Pharmaceuticals, Inc.
University of Arizona
University of Hawaii
University of Vermont


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services